- Home
- SYRE vs ULCC Comparison
SYRE vs ULCC Comparison
Compare SYRE & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- ULCC
- Stock Information
- Founded
- SYRE 2013
- ULCC 1994
- Country
- SYRE United States
- ULCC United States
- Employees
- SYRE N/A
- ULCC N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- ULCC Air Freight/Delivery Services
- Sector
- SYRE Health Care
- ULCC Consumer Discretionary
- Exchange
- SYRE Nasdaq
- ULCC Nasdaq
- Market Cap
- SYRE 841.4M
- ULCC 719.5M
- IPO Year
- SYRE 2016
- ULCC 2021
- Fundamental
- Price
- SYRE $15.30
- ULCC $4.02
- Analyst Decision
- SYRE Buy
- ULCC Hold
- Analyst Count
- SYRE 6
- ULCC 11
- Target Price
- SYRE $55.00
- ULCC $5.56
- AVG Volume (30 Days)
- SYRE 490.0K
- ULCC 3.7M
- Earning Date
- SYRE 05-08-2025
- ULCC 05-01-2025
- Dividend Yield
- SYRE N/A
- ULCC N/A
- EPS Growth
- SYRE N/A
- ULCC N/A
- EPS
- SYRE N/A
- ULCC 0.30
- Revenue
- SYRE N/A
- ULCC $3,822,000,000.00
- Revenue This Year
- SYRE N/A
- ULCC $4.58
- Revenue Next Year
- SYRE N/A
- ULCC $13.93
- P/E Ratio
- SYRE N/A
- ULCC $13.54
- Revenue Growth
- SYRE N/A
- ULCC 5.99
- 52 Week Low
- SYRE $10.91
- ULCC $2.79
- 52 Week High
- SYRE $40.26
- ULCC $10.26
- Technical
- Relative Strength Index (RSI)
- SYRE 51.16
- ULCC 52.46
- Support Level
- SYRE $14.87
- ULCC $3.60
- Resistance Level
- SYRE $15.71
- ULCC $4.38
- Average True Range (ATR)
- SYRE 0.72
- ULCC 0.25
- MACD
- SYRE 0.10
- ULCC 0.04
- Stochastic Oscillator
- SYRE 51.57
- ULCC 46.67
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.